Texas Permanent School Fund Nektar Therapeutics Transaction History

Texas Permanent School Fund

$597 Billion
Q3 2024

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 01, 2023	BUY	$0.64 - $3.15 $27,402 - $134,873	42,817 Added 34.05%	168,558 $117,000
Q4 2022 Feb 07, 2023	SELL	$2.03 - $4.28 $17,183 - $36,230	-8,465 Reduced 6.31%	125,741 $284,000
Q3 2022 Oct 25, 2022	BUY	$3.04 - $5.14 $799 - $1,351	263 Added 0.2%	134,206 $429,000
Q2 2022 Aug 08, 2022	BUY	$3.17 - $6.17 $9,830 - $19,133	3,101 Added 2.37%	133,943 $509,000
Q1 2022 May 06, 2022	SELL	$4.16 - $13.72 $9,226 - $30,430	-2,218 Reduced 1.67%	130,842 $705,000
Q4 2021 Feb 08, 2022	SELL	$10.83 - $18.41 $31,450 - $53,462	-2,904 Reduced 2.14%	133,060 $1.8 Million
Q3 2021 Oct 28, 2021	BUY	$13.07 - $18.84 $1,346 - $1,940	103 Added 0.08%	135,964 $2.44 Million
Q2 2021 Jul 27, 2021	SELL	$16.52 - $20.4 $4,063 - $5,018	-246 Reduced 0.18%	135,861 $2.33 Million
Q1 2021 May 03, 2021	SELL	$16.56 - $25.46 $131,519 - $202,203	-7,942 Reduced 5.51%	136,107 $2.72 Million
Q4 2020 Feb 04, 2021	SELL	$15.77 - $19.03 $364,018 - $439,269	-23,083 Reduced 13.81%	144,049 $2.45 Million
Q3 2020 Nov 06, 2020	BUY	$16.59 - $24.79 $439,717 - $657,058	26,505 Added 18.85%	167,132 $2.77 Million
Q2 2020 Aug 04, 2020	SELL	$16.86 - $23.44 $155,516 - $216,210	-9,224 Reduced 6.16%	140,627 $3.26 Million
Q1 2020 Apr 27, 2020	BUY	$14.47 - $27.96 $427,139 - $825,351	29,519 Added 24.53%	149,851 $2.68 Million
Q4 2019 Feb 03, 2020	BUY	$15.87 - $23.12 $1.4 Million - $2.03 Million	87,971 Added 271.84%	120,332 $2.6 Million
Q3 2019 Oct 31, 2019	SELL	$16.91 - $36.27 $21,205 - $45,482	-1,254 Reduced 3.73%	32,361 $589,000
Q2 2019 Aug 09, 2019	SELL	$31.0 - $36.3 $7,905 - $9,256	-255 Reduced 0.75%	33,615 $1.2 Million
Q1 2019 May 02, 2019	SELL	$31.58 - $46.35 $29,811 - $43,754	-944 Reduced 2.71%	33,870 $1.14 Million
Q4 2018 Feb 11, 2019	SELL	$30.43 - $56.65 $118,768 - $221,104	-3,903 Reduced 10.08%	34,814 $1.14 Million
Q3 2018 Oct 22, 2018	SELL	$46.46 - $68.49 $27,876 - $41,094	-600 Reduced 1.53%	38,717 $2.36 Million
Q2 2018 Jul 23, 2018	SELL	$46.25 - $104.45 $104,663 - $236,370	-2,263 Reduced 5.44%	39,317 $1.92 Million
Q1 2018 Apr 20, 2018	SELL	$57.4 - $108.44 $3.72 Million - $7.03 Million	-64,863 Reduced 60.94%	41,580 $4.42 Million
Q4 2017 Jan 23, 2018	SELL	$23.02 - $60.5 $176,862 - $464,821	-7,683 Reduced 6.73%	106,443 $6.36 Million
Q3 2017 Nov 13, 2017	BUY	$17.79 - $24.0 $2.03 Million - $2.74 Million	114,126	114,126 $2.74 Million

Others Institutions Holding NKTR

# of Institutions

147

Shares Held

139M

Call Options Held

32.6K

Put Options Held

14.1K

Deep Track Capital, LP Greenwich, CT

15.9M
Shares

$16.4 Million
0.76% of portfolio
Black Rock Inc. New York, NY

15.2M
Shares

$15.6 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

13.1M
Shares

$13.5 Million
0.0% of portfolio
Eventide Asset Management, LLC Boston, MA

9.4M
Shares

$9.68 Million
0.22% of portfolio
Samlyn Capital, LLC New York, NY

9.2M
Shares

$9.48 Million
0.19% of portfolio

View Full List

About NEKTAR THERAPEUTICS

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $193M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

More about NKTR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Texas Permanent School Fund, based on Form 13F filings with the SEC.

News

Stay updated on Texas Permanent School Fund with notifications on news.

Account